和厚朴酚联合顺铂治疗人肺癌A549的实验研究-肿瘤学专业论文.docxVIP

2006年七年制研究生毕业论文 连续给药3周。D组(单纯顺铂组)，剂量为4mg／kg，腹腔给药，每周2 次，共4次。E组(高剂量和厚朴酚组)脂质体包裹的和厚朴酚25mg／kg， 溶于O．2ml生理盐水中，药物浓度为40％，每日腹腔给药，连续给药3 周。F组(高剂量和厚朴酚联合顺铂组)为D组和E组治疗的联合，脂 质体包裹的和厚朴酚药物浓度为40％，每日腹腔给药，连续给药3周。 顺铂剂量为4mg／kg，腹腔给药，每周2次，共4次。顺铂给药后4小时 再给予脂质体包裹的和厚朴酚。 观察裸鼠肿瘤大小，生存曲线，化疗毒副反应，并进行肿瘤组织免 疫组化和肿瘤细胞凋亡分析。 结果：本实验证明和厚朴酚与顺铂联合治疗A549肺癌导致更强的抗肿瘤 效应，小鼠没有明显的不良反应。研究结果提示联合组肿瘤明显小于对 照组(PO．05)，生存期显著长于对照组。肿瘤组织的病理切片HE染色 显示，联合治疗组的肿瘤组织中坏死区域明显大于对照组，免疫组化显一 示联合组肿瘤组织中新生血管密度显著低于对照组(P0．05)，TUNNEL 法显示联合治疗组中肿瘤细胞凋亡显著多于对照组。 结论：该项研究首次表明使用和厚朴酚与顺铂联合治疗恶性肿瘤，取得 了协同抗肿瘤效应，分析其机制可能为二者的联合协同抑制了肿瘤新生 血管形成、诱导了肿瘤细胞的凋亡，联合化疗治疗恶性肿瘤具有可行性。 关键词：和厚朴酚 顺铂 A549肺癌 抗血管生成 诱导凋亡 2  2006年七年制研究生毕业论文 Honokioh a potent chemotherapy combined with Cisplatin in human A549 Lung cancer models Graduate：Qiqi Jiang Superviser：Prof．Yu-quan Wei Members ofDirector：Prof．Lijuan Chen ABSTRACTS Purpose：Honokiol is a bioactive compound extracted from Magnolia,a plant widely used in traditional Chinese and Japanese herbs．It is known to possess potential anti—neoplastic and anti-angiogenic properties．DDP is a classic first line anti·tumor drug，though directly breaking DNA synthesis．In this investigation,we have implemented a treatment regimen of combining liposome encoding Honokiol and conventional chemotherapeutic drug Cisplatin to treat human A549 lung cancer in nude mice in order to explore the possibility ofcombined—therapeutic strategy for CanCer． Materials and Methods：In this experiment，A549 lung cancer model Was established in 6—8 weeks nude mice and thell treated with either soluble liposome(i．P．every day for three weeks)，liposome mediated Honokiol (5mg／kg or 25mg／kg i．p．every day for three weeks)，Cisplatin(4mg／Kg,i．p． twice a week for two weeks)，25mg／kg liposome mediated Honokiol with 3  2006年七年制研究生毕业论文 Cisplatin together or NS．Then observe the volume of tumor,survival rate of mice．side effects of chemotherapy,as well as make imnluno—histochernical analysis oftumor section and cheek the apoptosis oftumor cells． Results：The combination treatment of Honokiol